Who is the "King of Weight Loss Drugs"? The market seems to have an answer
I'm PortAI, I can summarize articles.
After the formation of a duopoly between Eli Lilly and Novo Nordisk in the GLP-1 weight loss drug market, Eli Lilly announced that its oral GLP-1 drug orforglipron showed significant efficacy and safety in Phase 3 trials. The CEO stated that orforglipron, as a once-daily pill, would provide a convenient option for users worldwide if approved, marking a shift in the GLP-1 field towards oral formulations, with Eli Lilly taking the lead in this area
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments